Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists
Jacinda C. Abdul‐Mutakabbir, Nicole Griffith, Ryan K. Shields, et al.
Infectious Diseases and Therapy (2021) Vol. 10, Iss. 4, pp. 2177-2202
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Navigating Available Treatment Options for Carbapenem-ResistantAcinetobacter baumannii-calcoaceticusComplex Infections
Ryan K. Shields, David L. Paterson, Pranita D. Tamma
Clinical Infectious Diseases (2023) Vol. 76, Iss. Supplement_2, pp. S179-S193
Open Access | Times Cited: 73
The Evolution of Antimicrobial Resistance in Acinetobacter baumannii and New Strategies to Fight It
Viola Camilla Scoffone, Gabriele Trespidi, Giulia Barbieri, et al.
Antibiotics (2025) Vol. 14, Iss. 1, pp. 85-85
Open Access | Times Cited: 2
Society of Critical Care Medicine 2024 Guidelines on Adult ICU Design: Executive Summary
D. Kirk Hamilton, Jodie C. Gary, Elizabeth Scruth, et al.
Critical Care Medicine (2025) Vol. 53, Iss. 3, pp. e683-e689
Closed Access | Times Cited: 1
Acinetobacter baumannii : Pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline
Razieh Dehbanipour, Zohreh Ghalavand
Journal of Clinical Pharmacy and Therapeutics (2022) Vol. 47, Iss. 11, pp. 1875-1884
Open Access | Times Cited: 42
Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit
Steven Smoke, Alison Brophy, Samuel Reveron, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e1261-e1265
Open Access | Times Cited: 35
The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
Abdullah Tarık Aslan, Murat Akova
Antibiotics (2022) Vol. 11, Iss. 2, pp. 277-277
Open Access | Times Cited: 32
The Prevalence of Multidrug-Resistant Acinetobacter baumannii and Its Vaccination Status among Healthcare Providers
Ayman Elbehiry, Eman Marzouk, Ihab Mohamed Moussa, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1171-1171
Open Access | Times Cited: 20
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence
Marin H. Kollef, Hervé Dupont, David E. Greenberg, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106882-106882
Open Access | Times Cited: 19
A multiplex RPA coupled with CRISPR-Cas12a system for rapid and cost-effective identification of carbapenem-resistant Acinetobacter baumannii
Zihan Zhou, Lina Liang, Chuan Liao, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 6
Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii
Siqin Zhang, Lingfang Di, Qi Yan, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 6
Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients
Helen Giamarellou, Ilias Karaiskos
Antibiotics (2022) Vol. 11, Iss. 8, pp. 1009-1009
Open Access | Times Cited: 25
Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion
Nicola Coppola, Alberto Enrico Maraolo, Lorenzo Onorato, et al.
Antibiotics (2022) Vol. 11, Iss. 9, pp. 1263-1263
Open Access | Times Cited: 23
Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization
Giusy Tiseo, Cesira Giordano, Alessandro Leonildi, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 14
Targeting Acinetobacter baumannii resistance-nodulation-division efflux pump transcriptional regulators to combat antimicrobial resistance
Ruwani L. Wimalasekara, Dawn White, Ayush Kumar
npj Antimicrobials and Resistance (2025) Vol. 3, Iss. 1
Open Access
Society of Critical Care Medicine 2024 Guidelines on Adult ICU Design
D. Kirk Hamilton, Jodie C. Gary, Elizabeth Scruth, et al.
Critical Care Medicine (2025) Vol. 53, Iss. 3, pp. e690-e700
Closed Access
Antimicrobial susceptibility of gram-negative strains isolated from bloodstream infections in China: Results from the study for monitoring antimicrobial resistance trends (SMART) 2018–2020
Chen Yi-li, Pingjuan Liu, Huayin Li, et al.
Epidemiology and Infection (2025) Vol. 153
Open Access
Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
Sara Alosaimy, Taylor Morrisette, Abdalhamid M Lagnf, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 20
Anti-Acinetobacter baumannii single-chain variable fragments provide therapeutic efficacy in an immunocompromised mouse pneumonia model
Eilnaz Basardeh, Somayeh Piri‐Gavgani, Hamid Reza Moradi, et al.
BMC Microbiology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review
Guido Granata, Fabrizio Taglietti, Francesco Schiavone, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 12, pp. 3258-3258
Open Access | Times Cited: 12
Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killing
Andrew J Fratoni, Angela V Berry, Xiao Liu, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 9, pp. 2343-2353
Open Access | Times Cited: 7
Development of bacterial resistance in Germany from 2008 to 2022 — major culprit pathogens, antibacterial drugs, and prescribing practices
Lilly Josephine Bindel, Roland Seifert
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Open Access | Times Cited: 2
Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis
Masoumeh Beig, Elnaz Parvizi, Tahereh Navidifar, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0311124-e0311124
Open Access | Times Cited: 2
Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii
Suriya Chandran, Yuvasri Manokaran, Saranya Vijayakumar, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2023) Vol. 42, Iss. 5, pp. 645-651
Closed Access | Times Cited: 5
In vivo efficacy and PK/PD analyses of zifanocycline (KBP-7072), an aminomethylcycline antibiotic, against Acinetobacter baumannii in a neutropenic murine thigh infection model
Li Li, Xiaojuan Tan, Tianhua Zhou, et al.
Journal of Infection and Chemotherapy (2023) Vol. 30, Iss. 1, pp. 34-39
Closed Access | Times Cited: 5
Outcomes of adult patients with multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia treated with monotherapy versus combination therapy in a tertiary hospital
Leisa Jeanne Kaye Gobenciong Yee, Cybéle Lara R. Abad, Ian Theodore G. Cabaluna, et al.
Diagnostic Microbiology and Infectious Disease (2024) Vol. 110, Iss. 3, pp. 116481-116481
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top